- Previous Close
0.3000 - Open
0.3000 - Bid 0.2800 x --
- Ask 0.3200 x --
- Day's Range
0.3000 - 0.3000 - 52 Week Range
0.3000 - 11.8500 - Volume
14,201 - Avg. Volume
455,129 - Market Cap (intraday)
616,176 - Beta (5Y Monthly) -0.29
- PE Ratio (TTM)
0.01 - EPS (TTM)
24.7800 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida. Avenue Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.
www.avenuetx.comRecent News: ATXI
View MorePerformance Overview: ATXI
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATXI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATXI
View MoreValuation Measures
Market Cap
616.18k
Enterprise Value
-1.98M
Trailing P/E
0.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.24
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-471.94%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-18.28M
Diluted EPS (ttm)
24.7800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-10.1M